BUZZ-Rhythm rises as drug helps patients with rare form of obesity in small trial
Reuters
Jul 09
BUZZ-Rhythm rises as drug helps patients with rare form of obesity in small trial
** Shares of drugmaker Rhythm Pharmaceuticals RYTM.O rise 15.14% to $75 premarket
** Co tested its experimental drug bivamelagon in a mid-stage trial of 28 patients aged 12 years or older
** The drug showed reductions in body mass index at 14 weeks of treatment in patients with acquired hypothalamic obesity
** Co plans to seek input from U.S. and EU regulatory authorities on a late-stage trial design
** Acquired hypothalamic obesity is a rare form of obesity that occurs following damage to the hypothalamic region of the brain
** Up to last close, stock up ~16% YTD
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.